ReviewCureus2021
The Role and Validity of Diagnostic Biomarkers in Late-Onset Neonatal Sepsis.
Review in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Evaluation of umbilical cord blood presepsin in the diagnosis of neonatal early-onset sepsis.Frontiers in pediatrics · 2026Trial
- Investigating the effect of oropharyngeal colostrum in the prevention of late-onset sepsis in preterm infants: a randomized controlled trial.Scientific reports · 2025Trial
- Dynamic trajectories of inflammatory biomarkers and post-stroke cognitive impairment: a comprehensive review of neuroimmune mechanisms, longitudinal modeling, and clinical translation.Frontiers in neurology · 2026Review
- C-reactive Protein Versus Procalcitonin in the Early Diagnosis of Neonatal Sepsis: A Systematic Review.Cureus · 2025Review
- Understanding the Difficulties in Diagnosing Neonatal Sepsis: Assessing the Role of Sepsis Biomarkers.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2024Article
- Early Diagnostic Markers of Late-Onset Neonatal Sepsis.Pediatric reports · 2023Article
- The Role of Coagulase-Negative Staphylococci Biofilms on Late-Onset Sepsis: Current Challenges and Emerging Diagnostics and Therapies.Antibiotics (Basel, Switzerland) · 2023Review
- Fighting Antimicrobial Resistance in Neonatal Intensive Care Units: Rational Use of Antibiotics in Neonatal Sepsis.Antibiotics (Basel, Switzerland) · 2023Review
- Antimicrobial Peptides in Early-Life Host Defense, Perinatal Infections, and Necrotizing Enterocolitis-An Update.Journal of clinical medicine · 2022Review
- The Emerging Role of Presepsin (P-SEP) in the Diagnosis of Sepsis in the Critically Ill Infant: A Literature Review.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis remains a leading cause of mortality in the neonatal population, and currently, there is still no consensus on an accurate biomarker that can aid prompt diagnosis. This review focuses on studies investigating biomarkers for late-onset neonatal sepsis specifically. We discuss the current evidence for traditionally used biomarkers and present recent developments on more novel markers. Suitable articles were selected from PubMed, Embase, Medline, Cochrane Handbook of Systematic Reviews, and ScienceDirect. Inclusion criteria were studies published from 2010 to 2020. Exclusion criteria were animal model-based studies. Keywords in search strategy were late-onset neonatal sepsis + biomarkers + diagnosis. Evidence is growing increasingly weak for commonly studied biomarkers such as C-reactive protein (CRP) and procalcitonin (PCT). Levels of markers such as Serum Amyloid A and Neutrophil CD64 increase more rapidly post-onset of infection compared to CRP. Moreover, this review found that the more novel biomarkers discussed such as presepsin and endocan may show superior and more promising potential as diagnostic markers. However, larger studies over multicenters are deemed essential to ascertain the ideal biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.